Jalyn Approval History 
- FDA approved: Yes (First approved June 14th, 2010)
- Brand name: Jalyn
- Generic name: dutasteride and tamsulosin
- Company: GlaxoSmithKline
- Treatment for: Benign Prostatic Hyperplasia
Jalyn is a combination of dutasteride (5α-reductase inhibitor) and tamsulosin (alpha-adrenergic antagonist) indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
FDA Approval History for Jalyn
| Date | Article |
|---|---|
| Jun 14, 2010 |  FDA approves Jalyn, a fixed-dose combination of dutasteride and tamsulosin, for symptomatic BPH in men with an enlarged prostate |
See also...
Jalyn (dutasteride and tamsulosin) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
